This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus (Revised)
by Sriparna Ghosal
These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.
FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus
by Sriparna Ghosal
These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.
Bruker Inks Deal to Distribute Coronavirus Detection Test
by Zacks Equity Research
The agreement would make Bruker (BRKR) a key player in coronavirus diagnosis.
Quest Diagnostics Prioritizes Patients With Risk of Coronavirus
by Zacks Equity Research
The initiative will make Quest Diagnostics (DGX) one of the active players that are combating the public health crisis.
Intel, Royal Caribbean Cruises, Roche, Thermo Fisher and Quest Diagnostics highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Intel, Royal Caribbean Cruises, Roche, Thermo Fisher and Quest Diagnostics highlighted as Zacks Bull and Bear of the Day
QIAGEN Gets CE Nod for QIAstat-Dx Respiratory SARS-CoV-2 Test
by Zacks Equity Research
The regulatory clearance of this test has made QIAGEN (QGEN) a key player in coronavirus diagnosis.
Coronavirus Testing Players Gain Momentum: 3 Stocks in Focus
by Sriparna Ghosal
There are several key diagnostic testing laboratory and biotech players whose prospects seem bright on account of rigorous work on developing diagnostic testing for the coronavirus.
Quest Diagnostic Grows on New Acquisitions Amid Low Volume
by Zacks Equity Research
Quest Diagnostics' (DGX) latest strategic acquisitions act as major growth catalysts.
Thermo Fisher (TMO) Gets EUA From FDA for COVID-19 Testing
by Zacks Equity Research
The emergency authorization of this test has made Thermo Fisher (TMO) a key player in the field of coronavirus diagnosis.
Quest Diagnostics (DGX) to Launch Coronavirus Test Service
by Zacks Equity Research
Quest Diagnostics (DGX) aims to mobilize effective public health response to the coronavirus outbreak through quality laboratory testing.
LabCorp (LH) Launches Test to Detect Presence of Coronavirus
by Zacks Equity Research
LabCorp (LH), with an aim to contain the outbreak of coronavirus, launches the LabCorp 2019 Novel Coronavirus (COVID-19), NAA test.
Why Is Quest Diagnostics (DGX) Down 5.3% Since Last Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics (DGX) Q4 Earnings Beat, Margins Strong
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to expedite volume growth in Q4.
Quest Diagnostics (DGX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.37% and 0.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Quest Diagnostics (DGX) gains from several positive developments like partnerships and acquisitions.
Quest Diagnostics to Buy Select Assets of Memorial Hermann
by Zacks Equity Research
The acquisition is a step forward in Quest Diagnostics' (DGX) commitment toward offering high-quality, cost-efficient diagnostic services in Texas,especially the Houston metropolitan area.
New Alliances Aid Quest Diagnostics Despite Reimbursement Woes
by Urmimala Biswas
Quest Diagnostics (DGX) is currently concentrating on diagnostic information services arm and disciplined capital deployment.
Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.
DGX or ADUS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DGX vs. ADUS: Which Stock Is the Better Value Option?
Bright Near-Term Outlook for Medical Info Systems Industry
by Sreyoshi Mukherjee
As the healthcare industry experiences rapid and unprecedented technological changes, let's take a look at a few promising medical info systems stocks.
Rosy Outlook for Outpatient and Home Healthcare Industry
by Trina Mukherjee
Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and participation in APM.
Here's Why You Should Hold on to Quest Diagnostics Stock Now
by Zacks Equity Research
Investors can retain Quest Diagnostics (DGX) stock in their portfolio, thanks to solid prospects.
Quest Diagnostics (DGX) Up 1.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics (DGX) Q3 Earnings Surpass, View Strong
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to accelerate volume growth in Q3.